中证报中证网讯(王珞)近日，马来西亚首都吉隆坡迎来一场中医药国际交流盛会——"脑心同治理论与 实践国际研讨会暨国际脑心同治协会马来西亚分会成立大会"。来自中国、马来西亚、新加坡三国的两 百余名中西医医师齐聚一堂，共话健康福祉。 中国中西医结合学会脑心同治专业委员会主任委员赵超在大会上系统阐释了脑心同治理论的发展脉络与 核心价值：该理论由赵步长教授、伍海勤教授及赵涛博士共同提出，突破传统诊疗思维，将心脑两系视 为有机整体，强调从整体出发调和脏腑、平衡气血，为心脑血管疾病防治开辟了全新路径。经过数十年 的文献研究、实验验证与临床积累，这一理论已形成兼具科学性与先进性的创新体系，并被编入国家卫 生健康委员会"十三五"规划教材。此外，为推动理论落地，脑心同治专委会联合王永炎院士、张伯礼院 士等顶尖专家及科研机构成立脑心同治研究院，聚力攻克科研难题、推动成果转化；目前中国各省及地 级城市均已建立脑心同治学会，形成上下联动的发展格局；国际层面已相继成立印尼、加纳、哈萨克斯 坦等海外分会及中国香港地区分会，为全球医师学者搭建起常态化学术交流平台。 在全场嘉宾的共同见证下，大会举行了马来西亚脑心同治分会授牌仪式与脑心同治人才 ...

Group 1: Institutional Trading Insights - On the day, 41 stocks were listed on the institutional trading leaderboard, with 23 stocks seeing net purchases and 18 stocks experiencing net sales [1] - The top three stocks with the highest net purchases by institutions were: Xue Ren Co., Ltd. (¥182 million), International Composite Materials (¥145 million), and Ruikang Pharmaceutical (¥140 million) [1] Group 2: Stock Performance - Xue Ren Group (002639.SZ) saw a price increase of 0.85% with 4 buyers and no sellers [2] - International Composite Materials (301526.SZ) experienced a price increase of 6.48% with 3 buyers and 1 seller [2] - Ruikang Pharmaceutical (002589) had a significant price increase of 10.09% with 4 buyers and no sellers [2][3] Group 3: Industry Developments - Ruikang Pharmaceutical is identified as a comprehensive service provider in the traditional Chinese medicine industry, involved in planting and processing traditional Chinese medicine pieces [3] - The company has a subsidiary, Ma'anshan Jingquan Traditional Chinese Medicine, primarily engaged in the production and sales of traditional Chinese medicine pieces [3] - The report mentions the development of a free port-like economic zone in Xiamen as part of the city's 15th Five-Year Plan [3] Group 4: Optical Communication Sector - The optical communication sector is experiencing growth, with LightCounting projecting a compound annual growth rate (CAGR) of 17% for optical communication chipsets from 2025 to 2030, with total sales expected to rise from approximately $3.5 billion in 2024 to over $11 billion by 2030 [5] - Lumentum and Coherent have reached historical highs, indicating strong demand in the optical communication market [5] - A supply-demand gap for optical chips has increased to 25%-30%, with prices expected to rise by 2026 [5]

会上，"2026中医药呼吸健康发展共同体"成立。该共同体将聚焦呼吸疾病"预防—筛查—诊断—治疗— 康复"全周期管理，重点开展循证医学研究、适宜技术推广、人才联合培养等工作，致力于将个体化临 床经验转化为标准化诊疗路径，为完善全国呼吸疾病防治网络提供支撑。 共同体明确三大重点发展方向：科研层面，紧扣慢阻肺、哮喘等呼吸疾病诊疗痛点，深化产学研融合， 加速中医药新药创制与临床转化，建立"基础研究—临床试验—产品落地"全链条创新机制；学术传播层 面，启动"南山呼吸—岐黄之桥"专项活动，依托《南山呼吸》权威媒体平台，通过学术文章、深度访谈 等形式搭建中西医交流桥梁，推动中医药临床应用规范化；培训赋能层面，持续升级"呼吸健康万医 行"项目，在广州常态化开展线下培训，覆盖各级医疗机构呼吸科医生，推动医生专业培训与公众健康 科普双向赋能，助力提升行业诊疗水平与全民呼吸健康素养。(经济日报记者吴佳佳) 第二届中国呼吸健康大会日前在广州举办。大会由中国工程院院士钟南山、张伯礼共同担任主席。来自 呼吸病学、中医药学等领域的专家学者、行业代表参会，探索呼吸系统疾病筛、防、诊、治、康的创新 路径。 ...

Group 1 - The 2025 Changchun International Pharmaceutical and Health Industry Expo opened, featuring 41 enterprises from Hong Kong, Macau, Taiwan, and overseas Chinese communities showcasing health products and AI diagnostic equipment [1] - Exhibitors expressed a desire to establish closer cooperation with Jilin in the supply of ginseng and traditional Chinese medicine resources, highlighting Jilin's advantages in producing traditional medicine raw materials, particularly Changbai Mountain ginseng [1] - Companies like Shan Shen You Health Technology (Hong Kong) Co., Ltd. aim to leverage Jilin's raw material advantages to expand their product lines and increase production and sales scale, focusing primarily on the mainland market [1] Group 2 - The Taiwan Health Industry Alliance organized 17 enterprises focusing on biotechnology and health management, with companies like Meilian Biotechnology Co., Ltd. developing more efficient skin absorption products using nanotechnology [2] - Overseas Chinese enterprises are concentrating on supply chain stability and international market expansion, recognizing the growing global demand for traditional Chinese medicine [2] - The event serves as a platform for connecting raw material origins with markets, with hopes to promote deeper cooperation between Hong Kong, Macau, Taiwan enterprises and Jilin in the traditional medicine and ginseng industries [2]

Core Viewpoint - The traditional Chinese medicine industry is experiencing structural growth opportunities due to accelerated population aging and increasing health awareness among the public [1][3]. Group 1: Market Context - The prevalence of sub-health conditions such as insomnia, anxiety, forgetfulness, and palpitations is rising, making "nourishing the heart and calming the mind" a significant growth point in the health market [3]. - Over 300 million people in China suffer from sleep disorders, with a notable increase among the elderly population [3]. Group 2: Product Launch - The company has launched a new product, the "Renrong Anshen Wan," which targets heart and brain health, expanding its product matrix in the health sector [1][4]. - The formulation includes key ingredients like red ginseng and deer antler, along with other traditional herbs, adhering to traditional Chinese medicine principles [3]. Group 3: Quality Assurance - The company emphasizes high-quality raw materials, sourcing red ginseng from Jilin and deer antler from regulated farms, ensuring the purity and stability of active ingredients [3]. - Production follows national GMP standards and the company's high-quality management system [3]. Group 4: Market Performance - Since its launch, "Renrong Anshen Wan" has been well-received, particularly among the elderly and high-pressure working populations, with a steady increase in repurchase rates [4]. - The company ranks first in brand value among "Chinese Time-honored Brands" with a valuation of 43.739 billion yuan, reflecting strong market trust [4]. Group 5: Future Strategy - The launch of "Renrong Anshen Wan" is part of the company's broader strategy to deepen its presence in the health sector, focusing on creating safe, effective, and reliable health products [4].

中新网襄阳12月7日电 (杜斐 康健)"两岸同心 '襄'约美好——鄂台健康饮食文化交流活动"7日在湖北襄阳 市襄州区鹿门山举行，两岸33支药膳制作团队，通过精心烹制、创意呈现，展现药膳食疗魅力，增进文 化交流、技艺切磋、情感联结。 台湾药膳制作团队展台吸引不少观众。(襄阳融媒体中心供图) 来自台湾的一个药膳制作团队，现场展示了"台湾麻油鸡"烹制过程。该团队负责人对襄阳市中医医院团 队的"参鹿和鸣 两岸一心"药膳制品印象深刻。这名负责人表示，两个团队采用的食材、药材存在诸多 相似。虽然药膳口味不同，但是对药膳养生、健康饮食的热爱与追求相同，这些来自于同根同源的文化 传承。 襄阳市中医医院团队介绍药膳制品。杨文军 摄 鄂台健康饮食文化交流活动举行。(襄阳融媒体中心供图) 此次活动由湖北省海峡两岸交流促进会主办，襄阳市海峡两岸交流促进会、襄阳市中医药学会、襄阳市 中医医院联合承办。活动现场，襄阳市中医医院医护还为市民、游客讲解中医药膳文化知识，提供健康 咨询，开展中医外治体验、八段锦教学等活动。(完) 作为活动承办单位之一，襄阳市中医医院药膳制作团队，带来"松间寻珍 四神归元"等多个药膳作品。 该院党委书记皮红林表 ...

Core Viewpoint - Dong-E E-Jiao announced a share buyback plan for the first time since its listing in 1996, with a total amount between 100 million and 200 million yuan, aimed at enhancing investor confidence and recognizing the company's intrinsic value [1][2]. Financial Performance - As of September 30, 2025, Dong-E E-Jiao reported total assets of 12.75 billion yuan and equity attributable to shareholders of 9.948 billion yuan, with a liquidity ratio of 9.823 billion yuan [3]. - The planned buyback amount represents only 1.57% of total assets, 2.01% of equity, and 2.04% of current assets [3]. - The company has maintained a high cash dividend policy since its listing, with cumulative dividends reaching 10.03 billion yuan and a consistent payout ratio of nearly 100% in recent years [3]. Revenue and Profit Growth - From 2020 to 2024, Dong-E E-Jiao's revenue grew from 3.409 billion yuan to 5.921 billion yuan, with a compound annual growth rate (CAGR) of 14.7%, while net profit increased from 43 million yuan to 1.557 billion yuan, achieving a CAGR of 187.3% [5]. - For the first three quarters of 2025, the company reported revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan, with a gross margin increase of 3.33 percentage points to 73.69% [5][6]. Research and Development - Dong-E E-Jiao invested 145 million yuan in R&D for the first three quarters of 2025, marking a 62.29% year-on-year increase, with total R&D expenses over the past three years amounting to 492 million yuan [1][6]. - The company has achieved significant R&D milestones, including the development of rapid preparation techniques for traditional products and recognition for its innovative treatments [6]. Strategic Partnerships - Dong-E E-Jiao is collaborating with China Resources Group to explore international markets and invest in a 1 billion yuan pharmaceutical industry fund, focusing on traditional Chinese medicine and synthetic biology [7].

Core Insights - The Ministry of Commerce reported that in 2024, the revenue of Chinese time-honored brands is expected to exceed 2 trillion yuan, with profits surpassing 350 billion yuan and overseas revenue exceeding 50 billion yuan, indicating a vibrant future for these brands [1] - Chinese time-honored brands are seen as "living fossils" of national craftsmanship and cultural memory, with their preservation and innovation being crucial for both brand sustainability and the promotion of traditional culture [1] Group 1: Development Trends - Recent years have shown a positive development trend for Chinese time-honored brands, characterized by intelligent, green, and integrated transformations [2] - In 2024, online sales for these brands are projected to grow significantly by 55.1%, with 13.7% of them engaging in international operations, reflecting the rapid expansion of domestic trends [2] - Despite these advancements, there are still challenges regarding international recognition, technological breakthroughs, and management flexibility that need to be addressed [2] Group 2: Strategic Recommendations - The unique strength of Chinese time-honored brands lies in their deep cultural roots and precise policy guidance, which are difficult to replicate [3] - It is recommended to leverage international experiences, enhance technological empowerment, and foster cultural integration to revitalize these brands [3] - Encouraging collaboration with research institutions for core technology development and integrating cutting-edge technology with traditional craftsmanship is essential [3] Group 3: Policy Support - There is a need for improved recognition and protection mechanisms for Chinese time-honored brands, including support for new store openings and innovative marketing strategies [4] - The balance between commercial and cultural value is crucial, guiding these brands to maintain their cultural essence while adapting to new consumer trends [4] - The path of inheritance for these brands reflects cultural confidence, while their innovation journey showcases the transformation of traditional industries [4]

Core Viewpoint - Yiling Pharmaceutical's product Qifang Nizhong Pian has been included in the national medical insurance directory, marking a significant milestone for the company and the innovation of traditional Chinese medicine [1][3]. Group 1: Product and Innovation - Qifang Nizhong Pian is the first innovative traditional Chinese medicine specifically indicated for the treatment of persistent allergic rhinitis, filling a clinical gap [1][3]. - The product received approval from the National Medical Products Administration in January 2025 and was launched in Macau in July 2025, becoming the first innovative traditional Chinese medicine registered in Macau [3]. - The inclusion in the medical insurance directory is a recognition of the product's innovation, clinical efficacy, and safety, which will significantly enhance its accessibility and affordability [3]. Group 2: R&D Investment and Achievements - Yiling Pharmaceutical has maintained a high level of R&D investment, with R&D expenses reaching 544 million yuan in the first three quarters of 2025, accounting for 9.27% of revenue [4]. - From 2019 to 2024, the company’s cumulative R&D investment exceeded 5 billion yuan, consistently leading the industry average [4]. - The company has developed 17 patented traditional Chinese medicines covering eight major clinical disease systems, with 12 products included in the national medical insurance directory and 5 in the national essential drug list [4]. Group 3: Future Prospects and Team Structure - Yiling Pharmaceutical has a robust pipeline of products, with several traditional Chinese medicines and chemical drugs at various stages of clinical research and application [5]. - The company has established a high-quality research and management team, recognized as part of Hebei Province's "Giant Plan" and awarded multiple national and provincial scientific achievement awards [5]. - The company’s commitment to innovation and quality control positions it as a benchmark enterprise in the pharmaceutical industry, driving the development of traditional Chinese medicine [6].

Group 1 - The second China Respiratory Health Conference opened in Guangzhou, focusing on "Collaborative Innovation of Traditional and Western Medicine: Building a New Pattern of Respiratory Health" with over 2,000 experts and scholars in attendance [1] - The "2026 Respiratory Health Community" was established during the opening ceremony, with Tianyao Darentang being one of the first member units [3] - Tianyao Darentang, a traditional Chinese medicine company with a 500-year history, has a product portfolio of 599 drug approvals, including 122 exclusive varieties, covering various health areas [4] Group 2 - In the respiratory product line, Tianyao Darentang has 102 varieties, showcasing key products such as Qingyan Diban and Qingfei Xiaoyan Wan at the conference [5] - The company aims to protect and develop traditional Chinese medicine while promoting respiratory health, focusing on collaboration within the community to enhance innovation [5]